nach oben

Environmental Health and Preventive Medicine

Erschienen in:

01.01.2012 | Regular Article

C-reactive protein levels, airflow obstruction, and chronic kidney disease

verfasst von: Yayoi Funakoshi, Hisamitsu Omori, Shuichi Mihara, Ayumi Onoue, Yasuhiro Ogata, Hisamichi Aizawa, Takahiko Katoh

Erschienen in: Environmental Health and Preventive Medicine | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

Objectives

There is some evidence that chronic obstructive pulmonary disease and chronic kidney disease (CKD) may be related, perhaps through systemic inflammation, which is common to both. However, this relationship has not yet been clearly demonstrated. The aim of this study was to investigate the association between airflow obstruction, CKD, and C-reactive protein (CRP) levels in Japanese men.

Methods

The study included 11,587 men, aged 40–88 years, who underwent a health check-up. Airflow obstruction was defined as a forced expiratory volume in 1 s/forced vital capacity of <70%, and its severity was based on the Global Initiative for Chronic Obstructive Lung Disease guidelines (GOLD). CKD was defined as an estimated glomerular filtration rate of <60 mL/min/1.73 m².

Results

Airflow obstruction was present in 7.9% of the participants, and 10.6% of the participants had CKD. The average CRP levels were 0.11 ± 0.36, 0.13 ± 0.41, and 0.18 ± 0.41 mg/L for subjects with normal lung function, GOLD stage I, and GOLD stage II–IV, respectively. With regard to CKD, the average CRP levels were 0.11 ± 0.32 and 0.18 ± 0.6 mg/L for subjects without and with CKD, respectively. Analysis of covariance showed no significant differences between the CRP level and lung function status or CKD after age was adjusted for. Logistic regression analysis showed no association among subjects with the three different lung function statuses after age, body mass index, hypertension, diabetes, hyper-low-density-lipoprotein-cholesterolemia, smoking, physical activity, and alcohol intake were controlled for.

Conclusions

Based on the results of this study, we conclude that there is no interrelationship between CRP level, airflow obstruction, and CKD.

Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Global Initiative For Chronic Obstructive Lung Disease, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007;176:532–55.PubMedCrossRef

Global Initiative for Chronic Obstructive Lung Disease, April, 2001. Update 2009: Global Strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease, NHLBI/WHO Workshop Report (in Japanese). Bethesda, National Heart, Lung and Blood Institute. Available at: http://www.goldcopd.com. Accessed 13 Feb 2011.

Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet. 1997;349:1498–540.PubMedCrossRef

Fukuchi Y, Nishimura M, Ichinose M, Adachi M, Nagai A, Kuriyama T, et al. COPD in Japan: the Nippon COPD Epidemiology study. Respirology. 2004;9:458–65.PubMedCrossRef

Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet. 2007;370:765–73.PubMedCrossRef

Rutten FH, Cramer MJ, Lammers JW, Grobbee DE, Hoes AW. Heart failure and chronic obstructive pulmonary disease: an ignored combination? Eur J Heart Fail. 2006;8:706–11.PubMedCrossRef

Fabbri LM, Luppi F, Beghé B, Rabe KF. Complex chronic comorbidities of COPD. Eur Respir J. 2008;31:204–12.PubMedCrossRef

Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J. 2008;32:962–9.PubMedCrossRef

Eagan TM, Ueland T, Wagner PD, Hardie JA, Mollnes TE, Damås JK, et al. Systemic inflammatory markers in COPD: results from the Bergen COPD Cohort Study. Eur Respir J. 2010;35:540–8.PubMedCrossRef

10.

Spurzem JR, Rennard SI. Pathogenesis of COPD. Semin Respir Crit Care Med. 2005;26:142–53.

11.

Ninomiya T, Kiyohara Y, Kubo M, Tanizaki Y, Doi Y, Okubo K, et al. Chronic kidney disease and cardiovascular disease in a general Japanese population: the Hisayama Study. Kidney Int. 2005;68:228–36.PubMedCrossRef

12.

Kokubo Y, Nakamura S, Okamura T, Yoshimasa Y, Makino H, Watanabe M, et al. Relationship between blood pressure category and incidence of stroke and myocardial infarction in an urban Japanese population with and without chronic kidney disease: the Suita Study. Stroke. 2009;40:2674–9.PubMedCrossRef

13.

Nakayama M, Metoki H, Terawaki H, Ohkubo T, Kikuya M, Sato T, et al. Kidney dysfunction as a risk factor for first symptomatic stroke events in a general Japanese population—the Ohasama study. Nephrol Dial Transplant. 2007;22:1910–5.PubMedCrossRef

14.

Nakamura K, Okamura T, Hayakawa T, Kadowaki T, Kita Y, Ohnishi H, NIPPON DATA 90 Research Group, et al. Chronic kidney disease is a risk factor for cardiovascular death in a community-based population in Japan: NIPPON DATA 90. Circ J. 2006;70:954–9.PubMedCrossRef

15.

Imai E, Horio M, Watanabe T, Iseki K, Yamagata K, Hara S, et al. Prevalence of chronic kidney disease in the Japanese general population. Clin Exp Nephrol. 2009;13:621–30.PubMedCrossRef

16.

Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and meta-analysis. Thorax. 2004;59:574–80.PubMedCrossRef

17.

Fox ER, Benjamin EJ, Sarpong DF, Nagarajaro H, Taylor JK, Steffes MW, et al. The relation of C-reactive protein to chronic kidney disease in African Americans: the Jackson Heart Study. BMC Nephrol. 2010;11:1.PubMedCrossRef

18.

van Gestel YR, Chonchol M, Hoeks SE, Welten GM, Stam H, Mertens FW, et al. Association between chronic obstructive pulmonary disease and chronic kidney disease in vascular surgery patients. Nephrol Dial Transplant. 2009;24:2763–7.PubMedCrossRef

19.

Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, FitzGerald M, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J. 2008;31:143–78.PubMedCrossRef

20.

Funakoshi Y, Omori H, Mihara S, Marubayashi T, Katoh T. Association between airflow obstruction and the metabolic syndrome or its components in Japanese men. Intern Med. 2010;49:2093–9.PubMedCrossRef

21.

Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J. 2005;26:319–38.PubMedCrossRef

22.

The Japanese Respiratory Society. Statement of the Japanese Pulmonary Function Standard. Revised edition 2001 (in Japanese). Available at: http://www.jrs.or.jp/quicklink/glsm/guideline/nopass_pdf/spirogram.pdf Accessed 13 Feb 2011.

23.

Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.PubMedCrossRef

24.

Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2003;41:1–12.PubMedCrossRef

25.

Ogihara T, Kikuchi K, Matsuoka H, Fujita Higaki J, Horiuchi M, Imai Y, et al. The Japanese Societey of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res. 2009;32:3–107.PubMed

26.

Japan Atherosclerosis Society. Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular disease (in Japanese). J Atheroscler Thromb. 2007; 5–57.

27.

Kuzuya T, Nakagawa S, Satoh J, Kanazawa Y, Iwamoto Y, Kobayashi M, et al. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. Diabetes Res Clin Pract. 2002;55:65–85.PubMedCrossRef

28.

Iwamoto H, Yokoyama A, Kitahara Y, Ishikawa N, Haruta Y, Yamane K, et al. Airflow limitation in smokers is associated with subclinical atherosclerosis. Am J Respir Crit Care Med. 2009;179:35–40.PubMedCrossRef

29.

Soriano JB, Visick GT, Muellerova H, Payvandi N, Hansell AL. Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. Chest. 2005;128:2099–107.PubMedCrossRef

30.

Maqnussen H, Watz H. Systemic inflammation in chronic obstructive pulmonary disease and asthma: relation with comorbidities. Proc Am Thorac Soc. 2009;6:648–51.CrossRef

31.

Boulet LP. Influence of comorbid conditions on asthma. Eur Respir J. 2009;33:897–906.PubMedCrossRef

32.

Cazzola M, Calzetta L, Bettoncelli G, Novelli L, Cricelli C, Rogliani P. Asthma and comorbid medical illness. Eur Respir J. 2010. doi:10.1183/09031936.00140310.

33.

Viegi G, Scognamiglio A, Baldacci S, Pistelli F, Carrozzi L. Epidemiology of chronic obstructive pulmonary disease (COPD). Respiration. 2001;68:4–19.PubMedCrossRef

Titel: C-reactive protein levels, airflow obstruction, and chronic kidney disease
verfasst von: Yayoi Funakoshi
Hisamitsu Omori
Shuichi Mihara
Ayumi Onoue
Yasuhiro Ogata
Hisamichi Aizawa
Takahiko Katoh
Publikationsdatum: 01.01.2012
Verlag: Springer Japan
Erschienen in: Environmental Health and Preventive Medicine / Ausgabe 1/2012
Print ISSN: 1342-078X
Elektronische ISSN: 1347-4715
DOI: https://doi.org/10.1007/s12199-011-0214-1

Springer Medizin

Abstract

Objectives

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2012

The influence of forest therapy camp on depression in alcoholics

Increased emergency department chief complaints of fever identified the influenza (H1N1) pandemic before outpatient symptom surveillance

The relation between ambulance transports stratified by heat stroke and air temperature in all 47 prefectures of Japan in August, 2009: ecological study

Influences of income and employment on psychological distress and depression treatment in Japanese adults

Abstracts from Nippon Eiseigaku Zasshi (Japanese Journal of Hygiene) vol. 66, no. 4

A new phase transition for EHPM from a paper-based journal to an on-line one